Aurora Cannabis (ACB) has been almost flat since it reported its earnings on February 11. To learn more about the company’s earnings, read Aurora Cannabis: Key Takeaways from Its Q2 Earnings. In this part, we’ll discuss analysts’ recommendations and target price.
In February, analysts’ consensus recommendation for Aurora Cannabis was a “buy.” The recommendation month-over-month from a total of six analysts remained unchanged. However, analysts were less bullish on the stock in February. Among the six analysts, two recommended a “strong buy,” two recommended a “buy,” one recommended a “hold,” and one recommended a “sell.”
The consensus target price for Aurora Cannabis in February is 13.7 Canadian dollars, which increased from 11.8 Canadian dollars. Aurora Cannabis closed at 9.2 Canadian dollars on February 19. The current target price would leave room for a 49% increase. The median target price for the stock was even higher at 15 Canadian dollars, which increased from 13 Canadian dollars a month ago.
Aurora’s peers (MJ) including Canopy Growth (WEED) and HEXO (HEXO) also have a consensus “buy” recommendation.
Next, we’ll discuss Aphria’s (APHA) target price.